MA56513A - Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie - Google Patents
Dégradation de protéine ciblée de parp14 pour une utilisation en thérapieInfo
- Publication number
- MA56513A MA56513A MA056513A MA56513A MA56513A MA 56513 A MA56513 A MA 56513A MA 056513 A MA056513 A MA 056513A MA 56513 A MA56513 A MA 56513A MA 56513 A MA56513 A MA 56513A
- Authority
- MA
- Morocco
- Prior art keywords
- parp14
- therapy
- protein degradation
- targeted protein
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56513A true MA56513A (fr) | 2022-04-27 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056513A MA56513A (fr) | 2019-06-19 | 2020-06-18 | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220388985A1 (fr) |
| EP (1) | EP3986887A1 (fr) |
| JP (1) | JP2022537349A (fr) |
| KR (1) | KR20220024098A (fr) |
| CN (1) | CN114206853A (fr) |
| AU (1) | AU2020296063A1 (fr) |
| BR (1) | BR112021025645A2 (fr) |
| CA (1) | CA3142002A1 (fr) |
| MA (1) | MA56513A (fr) |
| SG (1) | SG11202112980TA (fr) |
| WO (1) | WO2020257416A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200103760A (ko) | 2017-12-21 | 2020-09-02 | 리본 테라퓨틱스 인코포레이티드 | Parp14 억제제로서의 퀴나졸리논 |
| JP2024502467A (ja) * | 2021-01-08 | 2024-01-19 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ニンボリドアナログ及びその使用方法 |
| JP2024505228A (ja) * | 2021-01-29 | 2024-02-05 | ライボン・セラピューティクス・インコーポレイテッド | 炎症性疾患を処置する方法 |
| CN114890989B (zh) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | 一种含氮衍生物为Linker的HDAC8降解剂其制备方法和应用 |
| WO2024026081A1 (fr) | 2022-07-29 | 2024-02-01 | Ribon Therapeutics, Inc. | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie |
| US20240051946A1 (en) | 2022-07-29 | 2024-02-15 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3674302T3 (da) * | 2014-04-23 | 2023-04-03 | Incyte Holdings Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-oner og pyrazolo[3,4-c]pyridin-7(6h)-oner som inhibitorer af bet-proteiner |
| WO2017197056A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles |
| ES2965049T3 (es) * | 2017-07-12 | 2024-04-10 | Dana Farber Cancer Inst Inc | Compuestos para la degradación de la proteína tau |
-
2020
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/fr unknown
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 KR KR1020217041538A patent/KR20220024098A/ko unknown
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/fr active Pending
- 2020-06-18 CA CA3142002A patent/CA3142002A1/fr active Pending
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/zh active Pending
- 2020-06-18 AU AU2020296063A patent/AU2020296063A1/en active Pending
- 2020-06-18 MA MA056513A patent/MA56513A/fr unknown
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/ja active Pending
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en active Pending
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021025645A2 (pt) | 2022-02-01 |
| CA3142002A1 (fr) | 2020-12-24 |
| CN114206853A (zh) | 2022-03-18 |
| KR20220024098A (ko) | 2022-03-03 |
| SG11202112980TA (en) | 2021-12-30 |
| AU2020296063A1 (en) | 2021-12-23 |
| WO2020257416A1 (fr) | 2020-12-24 |
| US20220388985A1 (en) | 2022-12-08 |
| JP2022537349A (ja) | 2022-08-25 |
| EP3986887A1 (fr) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA56513A (fr) | Dégradation de protéine ciblée de parp14 pour une utilisation en thérapie | |
| MA53921A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| MA55511A (fr) | Inhibiteurs de protéine tyrosine phosphatase | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| DK3681500T3 (da) | Anvendelse af pilocarpinhydrochlorid til behandling af presbyopi | |
| BR112017023579A2 (pt) | combinação de um anticorpo cd30xcd16 com um antagonista de pd-1 para terapia | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| EA201492289A1 (ru) | Композиции, содержащие аптамер против pdgf и антагонист vegf | |
| IL277444A (en) | Ionic liquid preparations for the treatment of rosacea | |
| IL260222A (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SA518391831B1 (ar) | تركيبات وطرق لخفض تعبير البروتين تاو | |
| DK3743420T3 (da) | Heterocyclylamino-substituerede triazoler som modulatorer af rho-associeret proteinkinase | |
| DK3740222T3 (da) | Modificeret RAAV-capsidprotein til genterapi | |
| MA43587A (fr) | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 | |
| DK3532059T3 (da) | Kombinationsterapi med bromdomæne- og ekstraterminal proteinhæmmer | |
| IL289622A (en) | bcl-2 protein inhibitors | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| DK3271392T3 (da) | Midler til anvendelse ved terapeutisk eller profylaktisk behandling af myopia eller hyperopia | |
| BR112019007426A2 (pt) | método para reduzir a proteinúria em um sujeito humano que sofre de igan. | |
| DE102018221635B8 (de) | Kontaktierungsverfahren und System | |
| MA50383A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| IL288090A (en) | Expression of antigen-binding proteins in the nervous system | |
| MA55016A (fr) | Utilisation du spiropidion | |
| DK3898985T3 (da) | Proteinekspression i tandem | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression |